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Abstract
Background: Endothelin-1 and angiotensin II are strong vasoconstrictors. Patients with ischemic heart
disease have elevated plasma levels of endothelin-1 and angiotensin II and show increased vascular tone.
The aim of the present study was to examine the endothelin and angiotensin II receptor expression in
subcutaneous arteries from patients with different degrees of ischemic heart disease.
Methods: Subcutaneous arteries were obtained, by biopsy from the abdomen, from patients undergoing
coronary artery bypass graft (CABG) surgery because of ischemic heart disease (n = 15), patients with
angina pectoris without established myocardial infarction (n = 15) and matched cardiovascular healthy
controls (n = 15). Endothelin type A (ETA) and type B (ETB), and angiotensin type 1 (AT1) and type 2 (AT2)
receptors expression and function were examined using immunohistochemistry, Western blot and in vitro
pharmacology.
Results: ETA and, to a lesser extent, ETB receptor staining was observed in the healthy vascular smooth
muscle cells. The level of ETB receptor expression was higher in patients undergoing CABG surgery (250%
± 23%; P < 0.05) and in the patients with angina pectoris (199% ± 6%; P < 0.05), than in the healthy controls
(100% ± 28%). The data was confirmed by Western blotting. Arteries from CABG patients showed
increased vasoconstriction upon administration of the selective ETB receptor agonist sarafotoxin S6c,
compared to healthy controls (P < 0.05). No such difference was found for the ETA receptors. AT1 and,
to a lesser extent, AT2 receptor immunostaining was seen in the vascular smooth muscle cells. The level
of AT1 receptor expression was higher in both the angina pectoris (128% ± 25%; P < 0.05) and in the
CABG patients (203% ± 41%; P < 0.05), as compared to the healthy controls (100% ± 25%). The increased
AT1 receptor expression was confirmed by Western blotting. Myograph experiment did however not
show any change in vasoconstriction to angiotensin II in CABG patients compared to healthy controls
(P = n.s).
Conclusion: The results demonstrate, for the first time, upregulation of ETB and AT1 receptors in
vascular smooth muscle cells in ischemic heart disease. These receptors may play a role in the
pathophysiology of ischemic heart disease and could provide important targets for pharmaceutical
interventions.
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Background
The renin-angiotensin and the endothelin systems are
essential in vascular homeostasis and may become mala-
daptive in cardiovascular diseases [1]. Angiotensin II and
endothelin-1 are formed in the endothelium and induce
potent vasoconstriction and proliferation of vascular
smooth muscle cells [2,3]. The continuous production of
endothelin-1 and angiotensin II in the endothelium is
important for the control of vessel tone and changes in the
endothelin- and renin-angiotensin-systems can give rise
to dysfunctional vessels such as those seen in patients
with cardiovascular risk factors [4]. Endothelin-1 and
angiotensin II have therefore been suggested to play a role
in the development if cardiovascular diseases, including
hypertension [5], chronic heart failure [6] and atheroscle-
rosis [7].
Endothelin-1 mediates its effects through two distinct G-
protein coupled receptors; the endothelin type A (ETA)
and type B (ETB) receptors. During physiologic condi-
tions, the ETA receptor is the dominant receptor subtype
expressed in vascular smooth muscle cells and mediates
contraction, while the ETB receptor is primarily located on
endothelial cells and mediates vasodilatation via the
release of nitric oxide and prostaglandins [8]. ETB recep-
tors on vascular smooth muscle cells have however been
observed to be upregulated during pathological condi-
tions such as atherosclerosis [9] and congestive heart fail-
ure [10]. Endothelin receptors on vascular smooth muscle
cells are both mitogenic, leading to atherosclerosis and
can induce strong vasoconstriction, resulting in elevated
vascular tone that contributes to the development of
ischemic cardiovascular disease.
Two angiotensin II receptors have been identified in man,
AT1 and AT2 receptors, which are members of the G-pro-
tein coupled seven-transmembrane domain receptor fam-
ily. The vascular effects of angiotensin II are primarily
mediated by AT1 receptors located on smooth muscle cells
which induce vasoconstriction and mitogenesis. Con-
versely, AT2 receptors are located on endothelial cells and
are known to induce vasodilatation, inhibit cell growth
and stimulate apoptosis [11]. AT2 receptors have been
shown, although to a lesser extent, in vascular smooth
muscle cells. Angiotensin II acts, apart from being a potent
vasoconstrictor also as a growth factor that regulates cell
growth, differentiation and fibrosis, as well as being
implicated in the pathology of heart failure, hypertension
and atherosclerosis [11].
In vivo studies on the effects of endothelin-1 and angi-
otensin II in the human peripheral vasculature have previ-
ously mainly been performed using a forearm blood flow
model. To the best of our knowledge, this is the first in
vitro study using peripheral vascular tissue samples iso-
lated from patients with different degrees of cardiovascu-
lar disease. The peripheral vasculature is contributing
significantly to total peripheral resistance leading to our
use of small peripheral arteries and arterioles, obtained
from the subcutaneous tissue in patients. Patients with
angina pectoris without established myocardial infarc-
tion, patients undergoing coronary artery bypass graft
(CABG) surgery because of ischemic heart disease and car-
diovascular healthy controls, were included in the study.
The expressions of endothelin ETA and ETB, and angi-
otensin AT1 and AT2 receptors in vascular smooth muscle
cells were studied by using immunohistochemistry, West-
ern blot and in vitro pharmacology.
Methods
Ethics
The project was approved by the Ethics Committee of
Lund University in Sweden (LU Dnr: 308/2004) and con-
forms to the principles outlined in the Declaration of Hel-
sinki. Each individual provided written consent to the
procedure.
Study groups
Three different groups of patients were included in the
immunohistochemistry part of the study.
1. Cardiovascular healthy controls (controls). This
group consisted of ten healthy volunteers without pre-
vious history of chest pain, cardiovascular disease or
prior cardiac medications. Blood samples for labora-
tory analysis were taken prior to the biopsy.
2. Fifteen patients with angina pectoris without estab-
lished myocardial infarction (patients with angina
pectoris). These patients were admitted to the medical
emergency unit with angina pectoris without signs of
prior or ongoing myocardial infarction as measured
by electrocardiogram and biomarkers for myocardial
injury. The patients had no history of heart failure.
Blood samples for laboratory analysis were taken at
the telemetry unit after the chest pain had resolved.
3. Patients undergoing coronary artery bypass graft
surgery (CABG) (n = 10). These patients underwent
elective CABG because of stabile ischemic heart dis-
ease confirmed by angiography revealing coronary dis-
ease in three arteries. The patients had no prior known
myocardial infarction but showed different degrees of
heart failure secondary to their heart vessel disorder.
Blood samples for laboratory analysis were taken the
day before the surgical intervention.
The patient background characteristics are defined in
Table 1.BMC Cardiovascular Disorders 2009, 9:40 http://www.biomedcentral.com/1471-2261/9/40
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Tissue collection
A biopsy was taken from the subcutaneous tissue of the
abdomen. For the control group and the patient with
angina pectoris, this was done during local anaesthesia (2
ml, 1% Xylocain; AstraZeneca, Sweden). For the patients
undergoing CABG surgery the biopsy was taken under
general anaesthesia during the initiation of surgery. A sub-
cutaneous tissue (1 cm3), containing small arteries, was
removed from the abdomen. The tissue was frozen in ice-
cold isopentane and stored at -80°C.
Immunohistochemistry
The biopsies were stored at -80°C prior to sectioning into
8-μm-thick slices in a calibrated Microm HM500M cryo-
stat (Microm). The sections were fixed and rehydrated in
phosphate-buffered saline (PBS). The sections were incu-
bated overnight with rabbit anti-human ETB (16207, IBL)
diluted 1:400, goat anti-human ETA (sc-21194, Santa Cruz
Biotechnologies) diluted 1:50, rabbit anti-human AT1 (sc-
1173, Santa Cruz Biotechnologies) diluted 1:50, rabbit
anti-human AT2 (sc-9040, Santa Cruz Biotechnologies)
diluted 1:50, mouse anti-human CD-31 (M0823, DAKO)
diluted 1:100 and mouse anti-human alpha-actin
(M0851, DAKO) diluted 1:1000. All dilutions were done
in PBS with 10% fetal calf serum. Antibodies to alpha-
actin were used to localize smooth muscle cells and anti-
bodies to CD-31 were used to localize endothelial cells.
The secondary antibodies used were donkey anti-rabbit
Cy™3 conjugated (711-165-152, Jackson ImmunoRe-
search) 1:100, donkey anti-goat Cy™3 conjugated (705-
165-003, Jackson ImmunoResearch) 1:100 and donkey
anti-mouse Texas Red conjugated (715-076-150, Jackson
ImmunoResearch) 1:200 in PBS. Only secondary antibod-
ies were used as control. The antibodies were directed
against a part of the respective receptor protein; this
amino acid sequence was used as a control to block the
antigenic site. The data from both immunocytochemistry
and Western blot are given at the respective company's
home page.
In vitro pharmacology
The resistance arteries were removed from the abdomen
from cardiovascular healthy patients undergoing abdom-
inal reduction surgery (n = 5) or during CABG surgery (n
= 5). The subjects had the same clinical characteristics as
those for immunohistochemistry (Table 1). Vessels were
placed in saline buffer on ice, transported to the labora-
tory and subsequently analyzed for their contractile prop-
erties in a myograph recording their isometric tension.
The vessels were cut into 1-mm-long cylindrical segments
and mounted on two L-shaped metal prongs, unilaterally
a force displacement transducer continuously recorded
the isometric tension [12]. Mounted vessel segments were
immersed in vessel baths at 37°C containing a bicarbo-
nate based buffer solution; NaCl (119 mM), NaHCO3 (15
mM), KCl (4.6 mM), CaCl2 (1.5 mM), MgCl (1.2 mM),
NaH2PO4 (1.2 mM), and glucose (5.5 mM). The buffer
was continuously aerated with oxygen enriched with 5%
CO2 resulting in pH 7.4. Initially vessels were stretched to
a resting tone of 2 mN and was then allowed to stabilize
at this tension for 1 h. Contractile capacity of each arterial
vessel segment was controlled by exposure to a potassium
rich (63.5 mM) buffer solution. Concentration-response
curves were obtained by cumulative application of
endothelin ETB receptor agonist, sarafotoxin 6c at increas-
ing concentrations (10-11-10-6 mM), ET-1 (AnaSpec, San
Jose, CA) in the concentration range 10-14 to 10-7 M and
angiotensin II in the concentration range 10-12 to 10-6 M.
Before the application of angiotensin II, the arteries were
pretreated with the AT2 receptor antagonist PD-123319
(10-5.5 M) for 30 min. After washout, the vessels returned
to baseline and endothelin-1 was then added at increasing
concentrations (10-11-10-6 mM) when endothelin ETBre-
ceptors were desensitized [13] facilitating endothelin-1 to
act solely on the endothelin ETA receptors. For details see
Nilsson et al. [14].
Table 1: Physical and Biochemical Characteristics in the Study 
Subjects
Variable Control
n = 10
Angina
n = 15
CABG
n = 10
Age (years) 62 ± 13 64 ± 13 70 ± 5
Smokers 2 4 1
SBP (mmHg) 125 ± 9 142 ± 15* 140 ± 14*
DBP (mmHg) 72 ± 8 76 ± 9 78 ± 12
Total cholesterol (mg/dl) 4.9 ± 1.6 5.3 ± 1.2 4.4 ± 2.4
LDL (mg/dl) 3.5 ± 0.7 3.5 ± 1.1 2.5 ± 1.6
HDL (mg/dl) 1.5 ± 0.5 1.5 ± 0.4 1.3 ± 0.5
Triglycerides (mg/dl) 1.5 ± 0.9 1.7 ± 1.0 1.9 ± 0.9
Apo lipoprotein A (mg/dl) 1.5 ± 0.3 1.6 ± 0.2 1.3 ± 0.5
Apo lipoprotein B (mg/dl) 0.9 ± 0.2 1.0 ± 0.3 0.9 ± 0.3
NYHA class
I1 0 1 0 4
II 0 0 4
III 0 0 2
IV 0 0 0
NT pro-BNP (ng/L) 106 ± 112 218 ± 243 1626 ± 2157*
C reactive protein (mg/dl) 2.1 ± 1.9 6.2 ± 15.3* 6.9 ± 6.1*
Beta blockers (n) 0 6 7
Statins (n) 0 5 8
ARB or ACEI (n) 0 3 6
HbA1c (%) 4.5 ± 0.5 4.7 ± 0.4 4.7 ± 0.8
BMI (kg/m2) 28 ± 2 29 ± 5 27 ± 3
Values are expressed as mean ± SD. Statistical analysis was performed 
using ANOVA with Dunnet's post-test for multiple comparisons. 
Significance was defined as P < 0.05 (*). Abbreviations are: CABG, 
coronary artery bypass graft surgery; SBP, systolic blood pressure; 
DBP, diastolic blood pressure; LDL, low-density lipoprotein 
cholesterol; HDL, high-density lipoprotein cholesterol; NYHA, New 
York Heart Association Functional Classification; NT-proBNP, N-
terminal pro B-type natriuretic peptide; ARB, angiotensin receptor 
blockers; ACEI, angiotensin converting enzyme inhibitors and BMI, 
body mass index.BMC Cardiovascular Disorders 2009, 9:40 http://www.biomedcentral.com/1471-2261/9/40
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The drugs used, endothelin-1 (ET-1), sarafotoxin 6c (S6c),
angiotensin II and PD-123319 were purchased from
Sigma Chemical Co (St. Louis, MO). They were dissolved
in 0.9% NaCl with 10% albumin.
Western Blot Analysis
Human vessels (4 from healthy donators and 5 from
CABG patients) were frozen in liquid nitrogen and
homogenized in cell extract denaturing buffer (BioSource,
USA) with addition of a protease inhibitor cocktail
(Sigma, USA). Whole cell lysates were sonicated for 2 min
on ice, centrifuged at 15,000 × g at 4°C for 30 min, and
the supernatants were collected as protein samples. The
protein concentrations were determined using the protein
assay reagents (Bio-Rad, Hercules, CA, USA) and stored at
-80°C until immunoblotting assay. The protein homoge-
nates were diluted 7:2:1(v/v) with 5× LDS Sample Buffer
and 10× DTT Reducer (PAGEgel, Inc. San Diego, CA,
USA). A total of 4050 μg of protein was boiled for 5 min
and separated by 412% SDS Ready Gels (PAGEgel, Inc.,
USA) for 120 min at 100 v, and transferred electrophoret-
ically to nitrocellulose membranes (Bio-Rad) at 100 v for
60 min. The membrane was then blocked for 1 h at room
temperature with phosphate buffered saline (PBS) con-
taining 0.1% Tween-20 (Sigma) and 5% non-fat dried
milk, and incubated with sheep anti-ETB (Enzo Life Sci-
ences Inc., Farmingdale, NY, USA), rabbit anti-AT1
(Abcam plc., Cambridge, UK), or rabbit anti-β-actin (Cell
Signaling Technology, Inc., Boston, MA, USA) polyclonal
primary antibodies diluted 1:200-500 overnight at 4°C,
followed by incubation with anti-sheep (Abcam plc., UK)
or anti-rabbit (Amersham Biosciences, Piscataway, NJ,
USA) IgG, horseradish peroxidase (HRP)-conjugated sec-
ondary antibodies diluted 1: 5000 for 1 h at room temper-
ature. The probed proteins were developed by LumiSensor
Chemiluminescent HRP Substrate kit (GenScript Corp.,
Piscataway, NJ, USA). To detect multiple signals using a
single membrane, the membrane was incubated for 515
min at room temperature with restored plus Western blot
stripping buffer (Pierce Biotechnology, Inc., Rockford, IL.
USA). The membranes were visualized using a Fujifilm
LAS-1000 Luminiscent Image Analyzer (Stamford, CT,
USA.). The quantification of band intensity was analyzed
with Image Gauge Ver. 4.0 (Fuji Photo Film Co., LTD.,
Japan). The expression of target proteins were presented as
a relative extent to the level of β-actin and normalized to
the percentage of control.
Calculations and statistics
Immunohistochemistry
The experiments were performed using arteries from 15
patients with angina pectoris, 10 patients undergoing
CABG surgery and 10 healthy controls. The samples were
examined in a fluorescence microscope (Olympus optical
Co, LTD, Bx60F5) and the absolute fluorescence intensity
was measured with ImageJ http://rsb.info.nih.gov/ij/.
Mean fluorescence values in the area selected were
obtained in three sections and at four different regions,
and the mean values were calculated. Statistical analysis
was performed using ANOVA with Bonferroni's or Dun-
net's post-test for multiple comparisons. Significance was
defined as P < 0.05 (*). The data are given in the text as
percentage difference relative to the mean fluorescence
seen in the control. The results are presented as mean val-
ues ± standard deviation (SD) and N equals number of
patients. Values are presented as percent fluorescence in
the angina and CABG groups compared with the control
patients group, where the control group is set to 100%.
In vitro pharmacology
The contractile reaction in each segment is expressed as
percentage of the 63.5 mM potassium induced contrac-
tion. Emax  value represents the maximum contractile
response elicited by an agonist, and the pEC50, the nega-
tive logarithm of the drug concentration that elicited half
the maximum response. Linear regression analysis was
applied using values obtained from above and below half-
maximum response for calculating the negative logarithm
of the concentrations that produced 50% contraction
(pEC50). Data are presented as mean ± standard error of
the mean (S.E.M). Statistical analyses was performed
using Student's t-test.
Western Blot
Comparisons between two groups were performed using
two-tailed unpaired Student's t-test. A p-value less than
0.05 were considered to be significant. Results were pre-
sented as mean ± S.E.M.
Results
Endothelin receptor expression
In healthy controls, the vascular smooth muscle cells
stained for ETA and, to a lesser extent, ETB receptors. The
immunostaining intensities for ETB receptors were higher
in arteries from the patients undergoing CABG surgery
(250% ± 23%; P < 0.05) and from the patients with
angina pectoris (199% ± 6%; P < 0.05), than from the
healthy controls (Figure 1 and 2). Furthermore, the levels
of ETB receptor expression were higher in the smooth mus-
cle cell layer in the arteries from the patients undergoing
CABG surgery than in the arteries from the patient with
angina pectoris (Figure 1B). The levels of ETA receptor
expression, in the smooth muscle cells, were similar in all
three groups (P = n.s.). In endothelial cells ETB receptor
immunostaining was primarily observed, however, it was
not different among the groups.
Western blot for ETB receptors detected a single band with
the approximate molecular weight of 53 kDa in the artery
homogenates from all samples including healthy controls
and patients undergoing CABG surgery (Figure 3). Densi-
tometric analysis showed that patients undergoing CABGBMC Cardiovascular Disorders 2009, 9:40 http://www.biomedcentral.com/1471-2261/9/40
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surgery had a mean increase of ETB receptors expression
(133 ± 8%; P < 0.05), which was significantly more than
in healthy controls (Figure 3)
Angiotensin II receptor expression
The vascular smooth muscle cells stained for AT1 and, to a
lesser extent, for AT2 receptors. The levels of AT1 receptor
expression were higher in both the angina pectoris (128%
± 25%; P < 0.05) and in the CABG patients (203% ± 41%;
P < 0.05), than from the healthy controls (Figure 2 and 4).
In addition, the levels of AT1 receptor expression were
higher in the smooth muscle cell layer in arteries from
patients undergoing CABG surgery than in arteries from
patient with angina pectoris (P < 0.05). AT2  receptor
expression was similar in all three groups. In endothelial
cells, only AT2 receptor immunostaining was observed.
Since the numbers of cells in the endothelial cell layer are
limited, no comparisons were made between the groups.
Western blot for AT1 receptors detected a single band with
the approximate molecular weight of 41 kDa in the artery
homogenates from all samples including healthy controls
and patients undergoing CABG surgery (Figure 3). Densi-
tometric analysis showed that patients undergoing CABG
surgery had a mean increase of AT1 receptors expression
(137 ± 9%; P < 0.05) which was significantly more than in
healthy controls (Figure 3).
Actin and CD-31 immunostaining
Double immunostaining showed co localization between
on one hand the AT1 and ETB receptors and on the other
hand smooth muscle cell alpha-actin in resistance arteries.
As shown in the illustration (Figure 5) there was clear co
localization between the two receptor subtypes and alpha-
actin both in control and in CABG subjects. CD-31 was
used to stain endothelial cells; we observed weak co local-
ization between both receptor and CD31 (Figure 5).
In vitro Pharmacology
The selective ETB receptor agonist S6c was used to study
ETB mediated contraction. Afterwards ET-1 induced vaso-
constriction was studied when endothelin B receptors
were desensitized by the previous application of S6c leav-
ETA (A) and ETB (B) receptor protein expression assessed by immunohistochemistry in human subcutaneous arteries Figure 1
ETA (A) and ETB (B) receptor protein expression assessed by immunohistochemistry in human subcutaneous 
arteries. Vessles were obtained from patients undergoing coronary artery bypass graft (CABG) surgery because of ischemic 
heart disease (n = 10), patients with angina pectoris without established myocardial infarction (n = 15) and cardiovascular 
healthy controls (n = 10). Values are expressed as mean ± SD. Statistical analysis was performed using ANOVA with Dunnet's 
post-test for multiple comparisons. Significance was defined as P < 0.05 (*).
Representative examples showing immunofluorescence stain- ing experiments for ETB and AT1 receptors in human subcu- taneous arteries Figure 2
Representative examples showing immunofluores-
cence staining experiments for ETB and AT1 recep-
tors in human subcutaneous arteries. Vessels were 
obtained from patients undergoing coronary artery bypass 
graft (CABG) surgery because of ischemic heart disease (n = 
10), patients with angina pectoris without established myo-
cardial infarction (n = 15) and cardiovascular healthy controls 
(n = 10). Note that the immunostaining intensity for both 
ETB and AT1 receptors, indicated with arrows, is higher in the 
arteries from patients with ischemic heart disease then from 
healthy controls. Magnification × 400 for all photomicro-
graphs.BMC Cardiovascular Disorders 2009, 9:40 http://www.biomedcentral.com/1471-2261/9/40
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ing only ETA receptors available for a contractile response.
Sarafotoxin 6c induced no vasoconstriction in healthy
control vessels. On the other hand patients undergoing
CABG showed a fairly strong and significant contractile
response to the cumulative application of S6c (P < 0.05 n
= 5) suggesting upregulation of ETB receptors at the func-
tional level (Figure 6A). Endothelin-1 induced a potent
vasoconstriction in both healthy controls and in patients
undergoing CABG surgery (P = ns) indicating that there
were no obvious changes in the ETA receptor responses
between the two groups (Figure 6B). Angiotensin II
induced concentration-dependent contractions of the
arteries were strong but there were no differences between
the groups (Figure 6C). The potassium rich buffer (124
mM) resulted in strong persistent contractions of the
resistance arteries with no differences between the groups
(data not shown).
Demographics
The patients' background characteristics are described in
Table 1. Taken together, the systolic blood pressure and C
reactive protein were higher in the patient with ischemic
heart disease (both CABG and angina pectoris). The
plasma levels of N-terminal pro B-type natriuretic peptide
(NT-proBNP) were higher in the CABG and the angina
pectoris groups than in the cardiovascular healthy con-
trols.
Discussion
Endothelin receptor expression and function
Our results clearly show that the level of ETB receptor
expression is higher in the vascular smooth muscle cell
layer of arteries from patients with angina pectoris than
from healthy controls. The levels of ETB receptor expres-
sion are even higher in arteries from patients undergoing
CABG surgery. We hypothesize that there is a progressive
upregulation of this receptor subtype that may correlate
with the degree of cardiovascular disease.
Upregulated ETB receptors on vascular smooth muscle
cells have previously been shown in diabetes, hyperten-
sion and in human atherosclerotic coronary arteries and
in atherosclerotic plaques [9,15,16]. Plasma levels of ET-1
are elevated in patients with ischemic heart disease and in
ETB (A) and AT1 (B) receptor protein expression in human subcutaneous arteries, examined using Western blot Figure 3
ETB (A) and AT1 (B) receptor protein expression in human subcutaneous arteries, examined using Western 
blot. Arteries from healthy control patients (n = 4) were compared with arteries from patients undergoing CABG surgery (n 
= 5). The results are shown as mean values ± S.E.M above the actual Western blot data with beta-actin as control. Statistical 
analyses was performed using Student's t-test, where P < 0.05 (*) was considered significant.BMC Cardiovascular Disorders 2009, 9:40 http://www.biomedcentral.com/1471-2261/9/40
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heart failure; it has been suggested as a prognostic marker
[17]. The circulating ET-1 levels are further increased in
patients undergoing CABG surgery [18]. This increased
activity in the endothelin system may contribute to
smooth muscle cell proliferation, vasoconstriction and
decreased perfusion in atherosclerotic disease [19-21].
Furthermore, CABG patients had significantly increased
pro-BNP levels indicating some degree of heart failure, a
condition associated with increased ETB receptor medi-
ated systemic vasoconstriction [22]. The elevated
endothelin ETB contraction in the present study, also veri-
fied by Western blot, indicates that the increased levels of
contractile endothelin ETB  receptors on the vascular
smooth muscle cells could play an important role in
ischemic heart disease since ETB receptor activation in
healthy controls did not induce any contractions at all.
Mechanisms underlying the upregulation of ETB receptors
The mechanism underlying the increased ETB receptor
expression is not known, but could depend on increased
transcription of ETB receptor mRNA triggered by some of
the many humeral factors that are increased in ischemic
heart disease. Upregulation of ETB receptors is known to
rely on increased transcription and subsequent transla-
tion of receptor mRNA [23]. In the human genome, the 5'-
flanking region of the genes encoding the endothelin
receptors contain several regulatory elements, like GATA-
motifs and E-boxes [24,25]. This indicates that the genes
might be activated by for example inflammatory compo-
nents. Indeed, the presence of interleukin-1β and TNF-α
may enhance the upregulation of vascular ETB receptors
[26]. In agreement, the patients with ischemic heart dis-
ease had higher plasma levels of C reactive protein.
Atherosclerosis is known to induce a proinflammatory
response [27] and this may in part regulate endothelin
receptor expression.
Angiotensin II receptor expression
In the present study, the levels of AT1 receptor expression
were higher in subcutaneous arteries from patients with
ischemic heart disease than in the healthy controls as ver-
ified by immunohistochemistry and Western blot. The
levels of expression were even higher in arteries from
patients undergoing CABG surgery. The plasma level of
angiotensin II is known to be elevated in different heart
conditions, such as heart failure [28], hypertension [29],
hypoxia [30], hypercholesterolemia [31] and hyperglyc-
emia [32]. We have found, herein, that this may be asso-
ciated with enhanced expression of vascular angiotensin II
receptors. Angiotensin II is a potent vasoconstrictor and
mitogen of coronary artery smooth muscle cells. The stim-
ulation of AT1 receptors results in progression of athero-
sclerotic lesions, inflammation and plaque rupture.
Increased expression of AT1 receptors might make the vas-
culature prone to develop spasm and atherosclerotic
plaques, and thus further increase peripheral vascular
resistance and reduce lumen. However, we did not
observe any enhanced contraction of angiotensin II medi-
ated via AT1 receptors as a result of an increased expression
in the myograph experiments. One explanation to this
could be the increased use of AT1 receptor antagonists in
patients undergoing CABG, thus blocking the AT1 recep-
tors. It is important, however, not to forget that AT1 recep-
tors apart from their contractile properties also possess
other abilities such as regulating cell growth, differentia-
tion and fibrosis which are important in the pathology of
heart failure, hypertension and atherosclerosis.
AT1 (A) and AT2 (B) receptor protein expression assessed by immunohistochemistry in human subcutaneous arteries Figure 4
AT1 (A) and AT2 (B) receptor protein expression assessed by immunohistochemistry in human subcutaneous 
arteries. Vessels were obtained from patients undergoing coronary artery bypass graft (CABG) surgery because of ischemic 
heart disease (n = 10), patients with angina pectoris without established myocardial infarction (n = 15) and cardiovascular 
healthy controls (n = 10). Values are expressed as mean ± SD. Statistical analysis was performed using ANOVA with Dunnet's 
post-test for multiple comparisons. Significance was defined as P < 0.05 (*).BMC Cardiovascular Disorders 2009, 9:40 http://www.biomedcentral.com/1471-2261/9/40
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Co localization of the AT1 and ETB receptors to vascular smooth muscle cells and endothelial cells Figure 5
Co localization of the AT1 and ETB receptors to vascular smooth muscle cells and endothelial cells. Immunos-
taining and co localization of the AT1 and ETB receptors to alpha-SMC and endothelin in resistance arteries of control patients. 
Antibodies to AT1 (green, A1, arrow) and smooth muscle actin (red, A2 arrow), A3 (merged A1 and A2). Antibodies to ETB 
(green, B1, arrow) and smooth muscle actin (red, B2, arrow), B3 (merged B1 and B2). Antibodies to AT1 (green, C1, arrow) and 
CD-31 (red, C2,arrow), C3 (merged C1+C2). Antibodies to ETB (green, D1, arrow) and CD-31 (red, D2, arrow), D3 (merged 
D1 and D2). Magnification × 400 for all photomicrographs.BMC Cardiovascular Disorders 2009, 9:40 http://www.biomedcentral.com/1471-2261/9/40
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Mechanisms underlying the upregulation of AT1 receptors
The mechanisms underlying the upregulation of AT1
receptor expression in patients with ischemic heart disease
cannot be deduced from the present study. Inflammatory
mediators, such as IL-1 and IL-6, may upregulate AT1
receptors and enhance angiotensin II stimulated vessel
hypertrophy [33]. In the present study, the observed
plasma levels of C reactive protein was elevated in patients
with ischemic heart disease. It has previously been shown
that high levels of C reactive protein correlate with high
levels of AT1 receptor expression [34]. Increased AT1 recep-
tor expression has therefore been associated with vascular
inflammation. C reactive protein is known to independ-
ently predict risk for myocardial infarction, stroke, periph-
eral artery disease and sudden cardiac death even among
apparently healthy individuals [35].
Clinical perspective
Both ET-1 and angiotensin II have strong impact on cardi-
ovascular diseases as discussed above; herein we will dis-
cuss their involvements in other situations: CABG surgery
is hampered by deleterious vasospasm in arterial grafts. It
has been suggested that impaired vasomotor function
may contribute to this vasospasm [36]. Plasma levels of
ET-1 and angiotensin II are elevated during CABG surgery
[18]. Both endothelin and angiotensin II receptors have
been shown to mediate strong vasoconstrictor effects in
bypass grafts [28]. Many measures have been undertaken
to control the vessel tone during surgery, including dilat-
ing the vessels with potent vasodilators such as papaver-
ine, sodium nitroprusside and nifedipine, or
mechanically distending the vessels with saline. It might
be important to consider endothelin and angiotensin II
receptor antagonists for this indication especially since
the present results show increased levels of endothelin
and angiotensin II receptor expression in patients under-
going CABG surgery.
Angiotensin converting enzyme inhibitors (ACEI) and
angiotensin AT1 receptor antagonists are frequently being
used to prevent the development of target organ damage
in atherosclerotic disease and in hypertension [37].
Whether endothelin receptor antagonists will become
part of the therapeutic armamentarium in ischemic heart
disease remains unclear, and none of these agents is cur-
rently being developed for this indication. However, the
mixed endothelin blocker Bosentan is used in treatment
of pulmonary hypertension [38] and other non-selective
ET receptor antagonists have been shown to inhibit the
development of atherosclerosis in experimental models
[39]. New endothelin antagonists devoid of side effects
and perhaps specific for either of the receptor subtypes are
discussed in treatment of vasospasm after subarachnoid
haemorrhage [40], or alternative inhibitors of the
endothelin converting enzymes that generate endothelin-
1 may in the future become available to block the
endothelin system [5].
Limitations
The present study has demonstrated increased expression
of ETB and AT1 receptors in patients with ischemic heart
disease. However, the patients have confounding factors.
The systolic blood pressure was higher in patients with
ischemic heart disease compared to the healthy controls.
Furthermore, the prevalence of medication with statins,
beta blockers, ACEI, and AT1 receptor antagonists was
In vitro pharmacology Figure 6
In vitro pharmacology. Concentration-response curves to increasing concentrations of (A) sarafotoxin 6c, (B) endothelin-1, 
and (C) angiotensin II in arteries from healthy controls (n = 5) and patients undergoing CABG surgery (n = 5). The results are 
shown as mean values ± S.E.M of five experiments in each group. Statistical analyses was performed using Student's t-test, 
where P < 0.05 (*) was considered significant.BMC Cardiovascular Disorders 2009, 9:40 http://www.biomedcentral.com/1471-2261/9/40
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common in patients with ischemic heart disease while
they were non-existing in our healthy controls. The effect
of these confounding factors on the endothelin and angi-
otensin II receptor expression cannot be concluded from
the present study.
Conclusion
The present study clearly shows that patients with
ischemic heart disease have upregulated ETB  and AT1
receptors in the smooth muscle cells of peripheral resist-
ance arteries. The level of ETB and AT1 expression corre-
lates with the degree of ischemic heart disease, being
highest in the patients undergoing CABG surgery. There
was no difference in the expression of ETA or AT2 receptors
between the study groups. The changes in ETB and AT1
receptor expression may be signs of remodeling of the vas-
culature, which is characteristic of ongoing ischemic heart
disease.
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